Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer

被引:2
作者
Gogate, Anagha [1 ]
Ranjan, Sandip [2 ]
Kumar, Amit [2 ]
Bhandari, Hitesh [2 ]
Papademetriou, Eros [3 ]
Kim, Inkyu [1 ]
Potluri, Ravi [3 ]
机构
[1] Bristol Myers Squibb, WWHEOR, Princeton, NJ 08540 USA
[2] SmartAnalyst India Pvt Ltd, HEOR, Gurgaon, India
[3] SmartAnalyst Inc, HEOR, New York, NY USA
来源
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词
HR; HER2-breast cancer; neoadjuvant; adjuvant; overall survival; surrogate endpoints; surrogate threshold effect; SURROGATE END-POINTS; PROGRESSION-FREE SURVIVAL; DISEASE-FREE SURVIVAL; BREAST-CANCER; CLINICAL-TRIALS; COLORECTAL-CANCER; CHEMOTHERAPY; THERAPY; TRASTUZUMAB; MULTICENTER;
D O I
10.3389/fonc.2023.1119102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The study's purpose was to evaluate the correlation between overall survival (OS) and its potential surrogate endpoints: pathologic complete response (pCR) and event-free survival (EFS)/disease-free survival (DFS) in neoadjuvant and/or adjuvant HR+/HER2- breast cancer. Methods Systematic search was performed in MEDLINE, EMBASE, Cochrane Library databases and other relevant sources to identify literature that have reported outcomes of interest in the target setting. The strength of correlation of EFS/DFS with OS, pCR with OS, and pCR with EFS/DFS was measured using Pearson's correlation coefficient (r) based on weighted regression analysis. For Surrogate Endpoint-True Endpoint pairs where correlation was found to be moderate, surrogate threshold effect (STE) was estimated using a mixed-effects model. Sensitivity analyses were conducted on the scale and weights used and removing outlier data. Results Moderate correlation was observed of relative measures [log(HR)] of EFS/DFS and OS (r = 0.91; 95% CI: 0.83, 0.96, p < 0.0001). STE for HREFS/DFS was estimated to be 0.73. Association between EFS/DFS at 1, 2 and 3 years with OS at 4- and 5-year landmarks was moderate. Relative treatment effects of pCR and EFS/DFS were not strongly associated (r: 0.24; 95% CI: -0.63, 0.84, p = 0.6028). Correlation between pCR and OS was either not evaluated due to inadequate sample size (relative outcomes) or weak (absolute outcomes). Results obtained in the sensitivity analyses were similar to base scenario. Conclusion EFS/DFS were moderately correlated with OS in this trial-level analysis. They may be considered as valid surrogates for OS in HR+/HER2- breast cancer.
引用
收藏
页数:10
相关论文
共 51 条
[1]   Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study [J].
Alba, E. ;
Calvo, L. ;
Albanell, J. ;
De la Haba, J. R. ;
Arcusa Lanza, A. ;
Chacon, J. I. ;
Sanchez-Rovira, P. ;
Plazaola, A. ;
Lopez Garcia-Asenjo, J. A. ;
Bermejo, B. ;
Carrasco, E. ;
Lluch, A. .
ANNALS OF ONCOLOGY, 2012, 23 (12) :3069-3074
[2]  
[Anonymous], 2005, EVALUATION SURROGATE, DOI DOI 10.1007/B138566
[3]  
[Anonymous], 2011, VAL SURR ENDP ONC
[4]   Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].
Atkinson, AJ ;
Colburn, WA ;
DeGruttola, VG ;
DeMets, DL ;
Downing, GJ ;
Hoth, DF ;
Oates, JA ;
Peck, CC ;
Schooley, RT ;
Spilker, BA ;
Woodcock, J ;
Zeger, SL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95
[5]   Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials [J].
Baker, Stuart G. .
STATISTICS IN MEDICINE, 2018, 37 (04) :507-518
[6]   The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018 [J].
Bruce, Catherine Schuster ;
Brhlikova, Petra ;
Heath, Joseph ;
McGettigan, Patricia .
PLOS MEDICINE, 2019, 16 (09)
[7]   Exploring and validating surrogate endpoints in colorectal cancer [J].
Burzykowski, Tomasz ;
Buyse, Marc ;
Yothers, Greg ;
Sakamoto, Junichi ;
Sargent, Dan .
LIFETIME DATA ANALYSIS, 2008, 14 (01) :54-64
[8]   Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer [J].
Cheema, P. K. ;
Burkes, R. L. .
CURRENT ONCOLOGY, 2013, 20 (02) :E150-E160
[9]  
Choudhary P, 2021, Cancer Res Stat Treat, V4, P611
[10]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172